Savara Inc (NASDAQ:SVRA) Shares Sold by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC lowered its holdings in Savara Inc (NASDAQ:SVRA - Free Report) by 41.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 410,586 shares of the company's stock after selling 289,414 shares during the period. Affinity Asset Advisors LLC owned about 0.24% of Savara worth $1,260,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in SVRA. Cibc World Markets Corp acquired a new stake in shares of Savara in the 4th quarter worth about $33,000. XTX Topco Ltd purchased a new position in shares of Savara in the fourth quarter worth approximately $34,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Savara during the fourth quarter valued at approximately $41,000. Jump Financial LLC acquired a new position in Savara in the 4th quarter worth approximately $64,000. Finally, Virtu Financial LLC purchased a new position in Savara during the 3rd quarter worth approximately $67,000. 87.93% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on SVRA shares. JMP Securities reissued a "market outperform" rating and set a $9.00 price target on shares of Savara in a research report on Thursday, December 19th. HC Wainwright reissued a "buy" rating and set a $6.00 target price on shares of Savara in a research report on Friday, March 28th. Finally, Wells Fargo & Company started coverage on Savara in a report on Friday, December 20th. They set an "overweight" rating and a $8.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $8.83.

Savara Stock Up 2.7 %

Shares of SVRA stock traded up $0.08 during mid-day trading on Friday, hitting $3.01. The stock had a trading volume of 465,408 shares, compared to its average volume of 1,315,597. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The firm has a market capitalization of $519.63 million, a P/E ratio of -7.00 and a beta of 0.52. Savara Inc has a 12-month low of $2.26 and a 12-month high of $5.31. The firm's 50-day moving average is $2.73 and its two-hundred day moving average is $3.10.

Savara (NASDAQ:SVRA - Get Free Report) last posted its earnings results on Thursday, March 27th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The firm had revenue of $0.27 million for the quarter. On average, analysts predict that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.